LIGELIZUMAB ACHIEVES FREEDOM FROM DISEASE ACTIVITY IN CHRONIC SPONTANEOUS URTICARIA REGARDLESS OF PREVIOUS H1-ANTIHISTAMINE DOSE

被引：0
|
作者：
Soong, W.
Sitz, K.
Bernstein, J.
Maurer, M.
Gimenez-Arnau, A.
Hua, E.
Severin, T.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2021年 / 127卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P049
引用
收藏
页码：S27 / S28
页数：2
相关论文
共 50 条
  • [41] EFFICACY AND SAFETY OF OMALIZUMAB IN H1-ANTIHISTAMINE-REFRACTORY CHRONIC IDIOPATHIC/SPONTANEOUS URTICARIA: RESULTS OF A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Saini, S. S.
    Bindslev-Jensen, C.
    Maurer, M.
    Grob, J. J.
    Baskan, E. Bulbul
    Bradley, M. S.
    Georgiou, P.
    Alpan, O.
    Spector, S.
    Rosen, K.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2013, 111 (05) : A18 - A18
  • [42] Barzolvolimab Significantly Decreases Chronic Spontaneous Urticaria Disease Activity and is Well Tolerated: Top Line Results from a Phase 2 Trial
    Maurer, Marcus
    Kobielusz-Gembala, Iwona
    Mitha, Essack
    Leflein, Jeffrey
    Gotua, Maia
    Kwiek, Bartlowmiej
    Metz, Martin
    Yellin, Michael
    Taglienti, Cherie
    Ma, Rick
    Alvarado, Diego
    Paradise, Elsa
    Bernstein, Jonathan
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 153 (02) : AB366 - AB366
  • [43] Comparably high Exposure to chronic spontaneous Urticaria in Patients with moderate and severe Disease Activity: Results from the ASSURE-csU Study
    Marsland, Alexander
    Abuzakouk, Mohamed
    Balp, Maria Magdalena
    Berard, Frederic
    Canonica, Giorgio Walter
    Gimenez-Arnau, Ana
    Grattan, Clive
    Hollis, Kelly
    Hunter, Shannon
    Khalil, Sam
    Knulst, Andre C.
    Lacour, Jean-Phillipe
    Lynde, Charles
    McBride, Doreen
    Nakonechna, Alla
    Ortiz De Frutoz, Francisco J.
    Elberink, J. N. G. Oude
    Sussman, Gordon
    Weller, Karsten
    Maurer, Marcus
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 9 - 10
  • [44] Chronic spontaneous/idiopathic urticaria patients with moderate activity have similar burden of disease as those with severe activity - results from the ASSURE-CSU study
    Marsland, A.
    Abuzakouk, M.
    Balp, M. M.
    Berard, F.
    Canonica, G. W.
    Gimenez-Arnau, A.
    Grattan, C.
    Hollis, K.
    Hunter, S.
    Khalil, S.
    Knulst, A. C.
    Lacour, J. P.
    Lynde, C.
    McBride, D.
    Nakonechna, A.
    Ortiz, De Frutoz F. J.
    Oude, Elberink J. N.
    Sussman, G.
    Tian, H.
    Weller, K.
    Maurer, M.
    ALLERGY, 2017, 72 : 95 - 95
  • [45] Angioedema and Angioedema Management From Asteria I and Asteria II: Phase III Studies To Evaluate The Efficacy and Safety Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment
    Zazzali, James
    Rosen, Karin
    Bradley, Mary S.
    Raimundo, Karina
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB117 - AB117
  • [46] Improvements In Health-Related Quality Of Life From Asteria I & II: Phase III Studies To Evaluate The Efficacy and Safety Of Omalizumab In Patients With Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment
    Raimundo, Karina
    Zazzali, James
    Trzaskoma, Benjamin
    Rosen, Karin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2014, 133 (02) : AB118 - AB118
  • [47] Treatment impact on quality of life of patients with chronic urticaria refractory to at least one course of H1 antihistamine therapy: Real-world evidence from AWARE-LACan study
    Dabove, F.
    Chiaverini, Ensina L. F.
    Velasquez-Lopera, M.
    Quijano, L. M. T.
    Berroa, F.
    Di Tata, F.
    Tassinari, P.
    ALLERGY, 2020, 75 : 198 - 198
  • [48] Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H 1-Antihistamines in Asia, Middle -East and Africa: Results from the AWARE-AMAC study
    Chu, Chia-Yu
    Al Hammadi, Anwar
    Agmon-Levin, Nancy
    Atakan, Nilgun
    Farag, Assem
    Arnaout, Rand K.
    Kannenberg, Suretha
    Kulthanan, Kanokvalai
    Mubarak, Asmara
    Zaitoun, Fares
    Crowe, Susanne
    Malfait, Sigrid
    Cooke, Kathryn
    Dekker, Elise L.
    WORLD ALLERGY ORGANIZATION JOURNAL, 2020, 13 (04):
  • [49] Initial results from BEACON, a phase 1b/2a dose escalation study of the anti-c-Kit briquilimab antibody in adults with chronic spontaneous urticaria (CSU)
    Casale, Thomas
    Tucker, Edwin
    Yuan, Jinwei
    Adelman, Daniel
    Ku, David
    Marcantonio, Annette
    Carlos, Patricia
    Majeed, Sophia
    Pang, Wendy
    Maurer, Marcus
    Metz, Martin
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2025, 155 (02) : AB435 - AB435
  • [50] Angioedema and angioedema management from ASTERIA II: a phase III, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of omalizumab in patients with chronic idiopathic/spontaneous urticaria (CIU/CSU) who remain symptomatic despite H1 antihistamine treatment
    Zazzali, J. L.
    Rosen, K. E.
    Hsieh, H-J
    ALLERGY, 2013, 68 : 43 - 43
12345